Expression and significance of MUC1 in endometrial carcinoma

Abstract

Objective To investigate the MUC1 expression in endometrial carcinoma and its clinical significance. Methods Twenty specimen of normal endometrial in proliferative phase, twenty specimen of atypical hyperplasia and fifty eight specimen of endometrial carcinoma were studied. Immunohistochemistry was used to study the expression of MUC1. Results The positive rates of MUC1 in endometrial carcinoma group and atypical hyperplasia group were 46.6% (27/58)and 35.0% (7/20), significantly higher than that in normal proliferative endometrial group (5% ,4/20). In endometrial carcinoma group the positive rate of MUC1 in FIGO stage Ⅱ and Ⅲ were respectively 57.9% (11/19) and 87.5% (7/8), significantly higher than that in stage Ⅰ (38.7% ,12/31), P ＜0.05 ,the positive rate of MUC1 in cases of deep myometrial invasion (78.3% , 18/23) was significantly higher that in superficial myometrial invasion (25.7% ,9/35), the positive rate of MUC1 in cases of positive lymph meststases (100% ,6/6), was significantly higher than that in cases of negative lymph meststases (40.4% ,21/52). Conclusions MUC1 may take part in the tumorigenesis, development and metastasis of endometrial carcinoma. Key words: Endometrialcarcinoma ; MUC1 ; Immunohistochemistry ;